Nov 23, 2020 / 01:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Eiger Zokinvy FDA Approval Conference Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference, Mr. Sri Ryali, Chief Financial Officer of Eiger BioPharmaceuticals. You may begin.
Sri Ryali - Eiger BioPharmaceuticals, Inc. - CFO
Thank you, and good morning and thank you everyone for joining us today. Welcome to Eiger's conference call to discuss the FDA approval of Zokinvy for Hutchinson-Gilford Progeria Syndrome, also known as Progeria and Processing-Deficient Progeroid Laminopathies and our plans for U.S. commercial launch.
We issued a press release Friday afternoon announcing FDA approval of Zokinvy and one this morning announcing the sale of the priority review voucher that was granted with this approval for $95 million.
Both press releases are available
Eiger BioPharmaceuticals Inc Call to Discuss Zokinvy FDA Approval Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers